NovaScan recently presented in a poster session at the 2018 Annual Meeting of the American Society of Breast Surgeons, where the company presented the results of a retrospective study that demonstrated that an elevated Cole frequency — which can be detected at the time of biopsy — has utility in predicting long term clinical outcomes.
NovaScan’s clinical results in Mohs surgery were published in the highly regarded Journal of the American Academy of Dermatology. The article, titled "Bioimpedance Measurement as an Assessment of Margin Positivity in Mohs Surgical Specimens of Non-Melanoma Skin Cancer: Management Implications" discussed the promising early results obtained by NovaScan in Mohs surgeries.
NovaScan was recently featured in the Milwaukee Journal Sentinel, describing our recent progress in commercializing our MarginScan device for use in Mohs procedures for skin cancer.
NovaScan participated in a poster session at the 2017 American College of Mohs Surgeons Annual Meeting, where the company presented A Rapid Method for Detecting Non-Melanoma Skin Cancer in Mohs Micrographic Surgery. The poster, which demonstrates how NovaScan can rapidly identify and locate cancer in Mohs procedures without histological assessment, was well received.
NovaScan Senior Scientist John Shell, Ph.D. has been selected to present in a poster session at a Special Topics Conference onHealthcare Innovations and Point of Care Technologies, co-sponsored by the National Institute of Health and IEEE. Dr. Shell will be presenting the “A Cancer Detection Device Using Multi-tiered Neural Networks for Improved Classification” during the poster session. In the poster and accompanying paper, Dr. Shell demonstrates how a neural network classification system led by assessment of the Cole relaxation frequency was employed by NovaScan to dramatically improve cancer detection in a mammography alternative.
PROPEL, dedicated to increasing the number and success rate of early-stage life sciences companies in Illinois, announced on April 19 at the 2016 Innovation Showcase on Day 1 of iBIO IndEx that NovaScan won the 2016 PROPEL Business Plan Competition. Over 300 community members watched Craig Davis, CEO of NovaScan, give the winning presentation to life sciences financial investor judges. PROPEL awarded NovaScan a $15,000 cash prize at the end of Tuesday's event. Congratulations to Craig and the entire NovaScan team!
From 2010-2015, NovaScan recieved National Science Foundation SBIR awards for Phase I, Phase Ia, Phase II and Phase IIb.
($2,291,925 — including investor match)
On a Thursday afternoon in November, a pea-sized lymph node from a mastectomy patient is brought into the crowded office of Dr. Gerald Smith, laboratory medical director at Aurora Sinai Medical Center. While the patient remains in the operating room, Smith freezes, slices, stains and microscopically examines the tissue for cancer. His conclusion will help determine if more of the woman's breast tissue or lymph nodes are removed. The process takes about 20 minutes.
Smtih's possible replacement for this procedure rests atop a table near his microscope—the FastPath Residual Cancer Probe. It's a cancer-detection device that inventor and physicist Bill Gregory, the chief science officer of NovaScan LLC, compares to a metal detector.
A local inventor is on the verge of groundbreaking breast cancer technology.
Cancer-scanning device detects residual cancer cells post-surgery—Biotech’s future